4.0 Review

Personalized medicine in psychiatry

期刊

NORDIC JOURNAL OF PSYCHIATRY
卷 71, 期 1, 页码 12-19

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1080/08039488.2016.1216163

关键词

Biomarkers; diagnostic system; genetics; personalized medicine; psychiatry; RDoC; taxonomy

资金

  1. Eli Lilly
  2. Janssen-Ortho
  3. Shire
  4. Astra-Zeneca
  5. Pfizer
  6. Lundbeck
  7. Sunovion
  8. Bristol-Myers Squibb

向作者/读者索取更多资源

Background: Personalized medicine is a model in which a patient's unique clinical, genetic, and environmental characteristics are the basis for treatment and prevention.Aim, method, and results: This review aims to describe the current tools, phenomenological features, clinical risk factors, and biomarkers used to provide personalized medicine. Furthermore, this study describes the target areas in which they can be applied including diagnostics, treatment selection and response, assessment of risk of side-effects, and prevention.Discussion and conclusion: Personalized medicine in psychiatry is challenged by the current taxonomy, where the diagnostic categories are broad and great biological heterogeneity exists within each category. There is, thus, a gap between the current advanced research prospects and clinical practice, and the current taxonomy is, thus, a poor basis for biological research. The discussion proposes possible solutions to narrow this gap and to move psychiatric research forward towards personalized medicine.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.0
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据